Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial

摘要

Background. This study validated a previously described diffusion MRI phenotype as a potential predictive imaging biomarker in patients with recurrent glioblastoma receiving bevacizumab (BEV).Methods. A total of 396/596 patients (66%) from the prospective randomized phase II/III EORTC-26101 trial (with n = 242 in the BEV and n = 154 in the non-BEV arm) met the inclusion criteria with availability of anatomical and diffusion MRI sequences at baseline prior treatment. Apparent diffusion coefficient (ADC) histograms from the contrast-enhancing tumor volume were fitted to a double Gaussian distribution and the mean of the lower curve (ADC(low)) was used for further analysis. The predictive ability of ADC(low) was assessed with biomarker threshold models and multivariable Cox regression for overall survival (OS) and progression-free survival (PFS).Results. ADC(low) was associated with PFS (hazard ratio [HR] = 0.625, P = 0.007) and OS (HR = 0.656, P = 0.031). However, no (predictive) interaction between ADC(low) and the treatment arm was present (P = 0.865 for PFS, P = 0.722 for OS). Independent (prognostic) significance of ADC(low) was retained after adjusting for epidemiological, clinical, and molecular characteristics (P = 0.02 for OS, P = 0.01 PFS). The biomarker threshold model revealed an optimal ADC(low) cutoff of 1241*10-6 mm(2)/s for OS. Thereby, median OS for BEV- patients with ADC(low) = 1241 was 10.39 months versus 8.09 months for those with ADC(low) 1241 (P = 0.004). Similarly, median OS for non-BEV patients with ADC(low) = 1241 was 9.80 months versus 7.79 months for those with ADC(low) 1241 (P = 0.054).Conclusions. ADC(low) is an independent prognostic parameter for stratifying OS and PFS in patients with recurrent glioblastoma. Consequently, the previously suggested role of ADC(low) as predictive imaging biomarker could not be confirmed within this phase II/III trial.